Biotech Mover: ZELTIQ Aesthetics, Inc.'s (ZLTQ)

Andrew Cummings
August 11, 2016

For the next 5 years, ZELTIQ Aesthetics, Inc.is expecting Growth of 30% per annum, whereas in the past 5 years the growth was 0% per annum. Zeltiq Aesthetics has been the topic of 10 analyst reports since August 26, 2015 according to StockzIntelligence Inc. (ZLTQ) is getting stronger by the bullish sentiment (1.5 on a 5-point scale) that sell-side analysts have provided concerning it. Brokerage firms on the average advocate the company shares as Buy. The difference between the expected and actual EPS was $-0.07/share, which represents an Earnings surprise of -140%.

Maxim Group gave shares of Zeltiq Aesthetics a price target of 48 indicating a potential increase of 41.68% from Zeltiq Aesthetics's current price of 33.88. The company's revenue was up 38.9% on a year-over-year basis. The 7 stock analysts who cover the stock have an average PT at $36.29, with individual targets in the range of $27 to $43.

During the 52-week period, the peak price level of the share was observed at $39.46; this is higher price of share and down price level of the share was seen at $18.41; this is lower price at which share is traded. The company stock was initiated at Buy, wrote analysts at Brean Capital, in a research note issued to clients on Wednesday April 13, 2016. 1,619,221 shares of the company were exchanged. The stock has a 50-day moving average price of $30.89 and a 200 day moving average price of $27.12. The last trading session volume compares with the 698.30K average and market worth floats around $1.34B. During the same quarter in the previous year, the business earned $0.03 earnings per share.


Analysts are projecting revenue of $323 million for 2016.

In related news, Director Kevin C. Oboyle sold 17,500 shares of the stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $31.21, for a total value of $312,100.00. Following the sale, the chief executive officer now owns 325,940 shares of the company's stock, valued at $10,172,587.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

An institutional investor recently raised its position in Zeltiq Aesthetics stock. California State Teachers Retirement System increased its stake in shares of Zeltiq Aesthetics Inc. The firm owned 59,726 shares of the company's stock after buying an additional 984 shares during the period.


On 8/9/2016, shares of Skyline Medical Inc.

While if we look at the Earnings Track Record, ZELTIQ Aesthetics, Inc. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is created to reduce stubborn fat bulges. The Company offers CoolSculpting System and other products to the dermatologists, plastic surgeons, and aesthetic specialists in North America and internationally.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER